A Phase III Confirmatory Study of K-877 Extended Release Tablet
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 356 participants.
Also called NCT04714151
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 356 participants
- Sponsor
- Registry
-
NCT04714151
-
- Other papers using this trial's data
- Efficacy and Safety of Pemafibrate Extended-Release Tablet: a Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Comparison Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT04714151. Randomized; quadruple masking; primary purpose treatment. Start 2021-02-01 (actual); primary completion 2021-09-25 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase III Confirmatory Study of K-877 Extended Release Tablet
- Condition
- Dyslipidemias
- Intervention (Drug)
- K-877 ER 0.2 mg/day (once daily)
- Intervention (Drug)
- K-877 ER 0.4 mg/day (once daily)
- Intervention (Drug)
- K-877 IR 0.2 mg/day (twice daily)
- Lead sponsor
- Kowa Company, Ltd.
Record details
- Record id
cardio:ct-nct04714151- Content hash
bcacf4b14f175935e904bc068c2c4010ebe49341ebf6c789ec14d7ea701badcb